Editas Medicine Inc
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
EDIT$2.51-8.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(amounts in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Cash flow from operating activities | |||
| Net loss | $(153,219) | $(220,432) | $(192,502) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Stock-based compensation expense | 19,798 | 29,294 | 43,399 |
| Depreciation | 6,064 | 6,337 | 5,053 |
| Net amortization of premiums and discounts on marketable securities | (4,823) | (724) | 1,657 |
| Other non-cash items, net | 1,596 | — | — |
| Changes in operating assets and liabilities: | |||
| Accounts receivable | (5,042) | (4,878) | 5,781 |
| Prepaid expenses and other current assets | (197) | (137) | 3,731 |
| Right-of-use assets | 9,968 | (17,475) | 9,691 |
| Other non-current assets | (3,335) | 1,558 | (2,108) |
| Accounts payable | (1,492) | 4,368 | (1,139) |
| Accrued expenses | 4,114 | 10,505 | (4,166) |
| Deferred revenue | — | (3,333) | (22,706) |
| Operating lease liabilities | (7,410) | 17,568 | (10,494) |
| Other current and non-current liabilities | 1,800 | — | — |
| Net cash used in operating activities | (132,178) | (177,349) | (163,803) |
| Cash flow from investing activities | |||
| Purchases of property and equipment | (4,719) | (4,118) | (7,977) |
| Proceeds from the sale of equipment | — | 18 | — |
| Purchases of marketable securities | (258,517) | (315,186) | (408,891) |
| Proceeds from maturities of marketable securities | 259,505 | 433,354 | 362,402 |
| Net cash provided by (used in) investing activities | (3,731) | 114,068 | (54,466) |
| Cash flow from financing activities | |||
| Proceeds from offering of common stock, net of issuance costs | 117,079 | — | 249,459 |
| Proceeds from exercise of stock options | 41 | 305 | 31,495 |
| Issuance of common stock under benefit plans | 919 | 979 | 1,152 |
| Net cash provided by financing activities | 118,039 | 1,284 | 282,106 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | (17,870) | (61,997) | 63,837 |
| Cash, cash equivalents, and restricted cash, beginning of period | 145,399 | 207,396 | 143,559 |
| Cash, cash equivalents, and restricted cash, end of period | $127,529 | $145,399 | $207,396 |
| Supplemental disclosure of cash and non-cash activities: | |||
| Fixed asset additions included in accounts payable and accrued expenses | $845 | $1,440 | $749 |
| Cash paid in connection with operating lease liabilities | 12,428 | 14,851 | 13,094 |
| Right-of-use assets obtained in exchange of operating lease obligations | 2,752 | 29,861 | 10,736 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.